<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071691</url>
  </required_header>
  <id_info>
    <org_study_id>A095007 (PITA)</org_study_id>
    <nct_id>NCT04071691</nct_id>
  </id_info>
  <brief_title>PET Imaging of Giant Cell and Takayasu Arteritis</brief_title>
  <acronym>PITA</acronym>
  <official_title>The PET Imaging of Giant Cell and Takayasu Arteritis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is often
      included in the diagnostic work-up of patients with large-vessel vasculitis (LVV), 18F-FDG
      lacks specificity for inflammatory cells and has limited ability to track therapy response.
      Moreover, high background 18F-FDG uptake in the brain and myocardium largely precludes
      imaging temporal arteritis in giant-cell arteritis (GCA) and coronary artery involvement in
      Takayasu arteritis respectively. These limitations of 18F-FDG for imaging LVV highlight
      important unmet clinical needs, which might be overcome by using a somatostatin receptor
      subtype-2 (SST2) PET tracer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up-regulation of SST2 in activated macrophages represents a novel imaging target for
      measuring vascular inflammation, which has been previously examined in atherosclerosis using
      68Ga-DOTATATE. To test the hypothesis that SST2 PET imaging can accurately identify LVV,
      patients with active GCA or Takayasu arteritis will undergo vascular 68Ga-DOTATATE or
      18F-fluoroethyltriazole-(Tyr3)-octreotate (FETO) PET-MRI at baseline, with repeat imaging
      after 6 months of treatment. A group of individuals with LVV in clinical remission will also
      undergo SST2 PET imaging. Data from patients with clinically inactive disease will serve to
      confirm tracer specificity for active disease, as well as signal reproducibility. 18F-FETO is
      an alternative SST2 tracer to 68Ga-DOTATATE; the longer half-life and shorter positron range
      of 18F compared to 68Ga may offer several advantages, including wider tracer availability and
      improved spatial resolution when imaging small arteries. All patients will also undergo
      18F-FDG imaging before treatment, where clinically indicated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of SST2 PET-MRI for LVV</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine the diagnostic accuracy of SST2 PET-MRI for LVV, with the clinically adjudicated diagnosis as the gold-standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>6 months</time_frame>
    <description>To compare vascular SST2 PET pre- and post-treatment for LVV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active versus inactive disease</measure>
    <time_frame>Baseline</time_frame>
    <description>To compare vascular SST2 PET in patients with active disease versus inactive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison with biochemical markers of disease severity</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>To compare SST2 PET to C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison with clinical measures of disease severity</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>To compare SST2 PET to clinical disease activity scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of SST2 PET tracers</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>To compare 68Ga-DOTATATE PET to 18F-FETO PET</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <condition>Takayasu Arteritis</condition>
  <arm_group>
    <arm_group_label>Active LVV</arm_group_label>
    <description>Patients with active LVV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable LVV</arm_group_label>
    <description>Patients with inactive LVV</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET-MRI</intervention_name>
    <description>SST2 PET-MRI scan</description>
    <arm_group_label>Active LVV</arm_group_label>
    <arm_group_label>Stable LVV</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with LVV
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants &gt;18 years old

          -  Able to give written, informed consent and to lie flat

          -  Either:

               1. New clinical diagnosis or acute flare of LVV (Giant-cell arteritis or Takayasu's
                  arteritis) within ~1 week of treatment initiation, and

               2. Clinical indication for 18F-FDG PET-CT scan determined by the referring
                  physician, or

               3. Undergoing surgery for LVV, or

               4. Diagnosis of LVV in remission

        Exclusion Criteria:

          -  Women of child bearing potential not using adequate contraception

          -  Contra-indication to MRI scanning

          -  Contrast allergy or contrast-nephropathy

          -  Chronic kidney disease (eGFR &lt;30 mL/min/1.73 m2)

          -  Any medical condition, in the opinion of the investigator, that prevents the
             participant from lying flat during scanning, or from participating in the study

          -  History of recent malignancy deemed relevant to the study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Tarkin, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason M Tarkin, MBBS PhD</last_name>
    <phone>+44(0)1223331504</phone>
    <email>jt545@cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M Tarkin, MBBS PhD</last_name>
      <email>jt545@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James HF Rudd, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Peters, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason M Tarkin, MBBS PhD</last_name>
    </contact>
    <contact_backup>
      <email>jt545@cam.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Justin C Mason, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, Rudd JH. Detection of Atherosclerotic Inflammation by (68)Ga-DOTATATE PET Compared to [(18)F]FDG PET Imaging. J Am Coll Cardiol. 2017 Apr 11;69(14):1774-1791. doi: 10.1016/j.jacc.2017.01.060.</citation>
    <PMID>28385306</PMID>
  </reference>
  <reference>
    <citation>Pedersen SF, Sandholt BV, Keller SH, Hansen AE, Clemmensen AE, Sillesen H, Højgaard L, Ripa RS, Kjær A. 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy. Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1696-703. doi: 10.1161/ATVBAHA.114.305067. Epub 2015 May 14.</citation>
    <PMID>25977567</PMID>
  </reference>
  <reference>
    <citation>Dubash SR, Keat N, Mapelli P, Twyman F, Carroll L, Kozlowski K, Al-Nahhas A, Saleem A, Huiban M, Janisch R, Frilling A, Sharma R, Aboagye EO. Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors. J Nucl Med. 2016 Aug;57(8):1207-13. doi: 10.2967/jnumed.115.169532. Epub 2016 May 12.</citation>
    <PMID>27173162</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Jason Tarkin</investigator_full_name>
    <investigator_title>Wellcome Clinical Research Career Development Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

